Summary

Industry Overview

The global adrenoleukodystrophy market is currently in the growth stage of its lifecycle. Having transitioned from the introduction phase, where treatment options were limited and awareness was low, the market is now experiencing increased interest due to advances in gene therapy-based treatments and innovative drug therapies. Rising diagnostic capabilities, such as newborn screening programs, have contributed to earlier detection, driving demand for therapeutic interventions. Furthermore, the emergence of orphan drug programs and government support for rare diseases has spurred market growth. However, the market still faces challenges, including high treatment costs and a relatively small patient base, which may limit rapid expansion. Overall, while the market is growing, it remains highly specialized and will continue to evolve the rare disease landscape with ongoing research and development.

Impact

• Increasing demand for adrenoleukodystrophy therapies is anticipated to support the growth of the global adrenoleukodystrophy market during the forecast period 2025-2035.
• The global adrenoleukodystrophy market is expected to grow at a significant rate due to developments in targeted therapies, rising awareness and diagnosis, and a growing clinical pipeline, alongside advancements in healthcare infrastructure and access to specialized treatments.
Recent Developments

• Research Activities: In December 2024, Minoryx Therapeutics and Neuraxpharm Group announced that leriglitazone met the primary endpoint in the NEXUS trial for paediatric patients with cerebral adrenoleukodystrophy (cALD).

Demand – Drivers and Limitations

Drivers:

• Increasing Prevalence of Adrenoleukodystrophy
• Advancements in Treatment Options
• Growing Research and Investment in Rare Diseases

Limitations:

• High Treatment Costs
• Limited Awareness in Developing Regions

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Innovations in the global adrenoleukodystrophy market are centered on advancing treatment options to enhance patient care. Key players in the market, such as Minoryx Therapeutics and NeuraxPharm, have been involved in the development of therapies for adrenoleukodystrophy.

Competitive Strategy: Enterprises led by market leaders continually update their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product pipeline and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolios, and market penetration.

Some of the prominent names established in this market are:

• bluebird bio
• Minoryx Therapeutics, S.L.
• MedDay Pharmaceuticals
• Viking Therapeutics
• Neuraxpharm Group

ページTOPに戻る

Table of Contents

Executive Summary
Scope of Study
1. Global Adrenoleukodystrophy Market Overview
1.1 Industry Outlook
1.1.1 Market Overview and Ecosystem
1.1.2 Market Trends
1.1.3 Epidemiological Analysis of Adrenoleukodystrophy
1.1.4 Clinical Trials
1.1.4.1 By Phase
1.1.4.2 By Sponsor Type
1.1.5 Regulatory Landscape / Compliance
1.2 Market Dynamics
1.2.1 Impact Analysis
1.2.2 Market Drivers
1.2.3 Market Restraints
1.2.4 Market Opportunities
2. Global Adrenoleukodystrophy Market (By Region), $Million, 2023-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Size and Forecast
2.1.2.1 North America Adrenoleukodystrophy Market (by Country)
2.1.2.1.1 U.S.
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Size and Forecast
2.2.2.1 Europe Adrenoleukodystrophy Market (by Country)
2.2.2.1.1 U.K.
2.2.2.1.2 Germany
2.2.2.1.3 France
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Size and Forecast
2.3.2.1 Asia-Pacific Adrenoleukodystrophy Market (by Country)
2.3.2.1.1 Japan
3. Global Adrenoleukodystrophy Market - Competitive Benchmarking and Company Profiles
3.1 Competitive Landscape
3.1.1 Key Strategies and Developments by Company
3.1.1.1 Funding Activities
3.1.1.2 Mergers and Acquisitions
3.1.1.3 Regulatory Approvals
3.1.1.4 Partnerships, Collaborations and Business Expansions
3.1.2 Key Developments Analysis
3.2 Company Profiles
3.2.1 bluebird bio
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Analyst View
3.2.2 Minoryx Therapeutics, S.L.
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers/End Users
3.2.2.4 Analyst View
3.2.3 MedDay Pharmaceuticals
3.2.3.1 Company Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers/End Users
3.2.3.4 Analyst View
3.2.4 Viking Therapeutics
3.2.4.1 Company Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers/End Users
3.2.4.4 Analyst View
3.2.5 Neuraxpharm Group
3.2.5.1 Company Overview
3.2.5.2 Product Portfolio
3.2.5.3 Target Customers/End Users
3.2.5.4 Analyst View
4. Research Methodology
List of Figures
Figure: Global Adrenoleukodystrophy Market, Market Overview
Figure: Global Adrenoleukodystrophy Market, Epidemiological Analysis, U.S.
Figure: Global Adrenoleukodystrophy Market Coverage
Figure: Global Adrenoleukodystrophy Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Adrenoleukodystrophy Market, Competitive Landscape, January 2022-April 2025
List of Tables
Table: Global Adrenoleukodystrophy Market, Regulatory Scenario
Table: Global Adrenoleukodystrophy Market Dynamics, Impact Analysis
Table: Global Adrenoleukodystrophy Market (by Region), $Million, 2023-2035

Press Release